Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.

Peskin BR, Shcheprov AV, Boye KS, Bruce S, Maggs DG, Gaebler JA.

Diabetes Obes Metab. 2011 Oct;13(10):921-7. doi: 10.1111/j.1463-1326.2011.01430.x.

PMID:
21624032
2.
3.

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.

Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.

PMID:
23748506
4.

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.

Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.

Vasc Health Risk Manag. 2012;8:255-64. doi: 10.2147/VHRM.S28744. Epub 2012 Apr 23.

5.

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.

Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M.

Diabetes Obes Metab. 2014 Jul;16(7):628-35. doi: 10.1111/dom.12261. Epub 2014 Feb 19.

PMID:
24443793
6.

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.

Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.

Diabetes Obes Metab. 2013 Mar;15(3):264-71. doi: 10.1111/dom.12026. Epub 2012 Nov 12.

7.

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.

Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.

Postgrad Med. 2012 Jul;124(4):33-40. doi: 10.3810/pgm.2012.07.2568.

PMID:
22913892
8.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
9.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

10.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
11.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
12.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

Diabetes Obes Metab. 2006 Jul;8(4):436-47.

PMID:
16776751
13.

Once-weekly exenatide as a treatment for Type 2 diabetes.

Schauerhamer MB, Gurgle H, McAdam-Marx C.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):611-26. doi: 10.1586/14779072.2015.1038242. Review.

PMID:
26000560
14.

Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial.

Ladhani NN, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Spooner R, Simpson SH.

Diabet Med. 2012 Nov;29(11):1433-9. doi: 10.1111/j.1464-5491.2012.03673.x.

PMID:
22486226
15.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
16.

The effect of intensive glycaemic control on cardiovascular outcomes.

Hill D, Fisher M.

Diabetes Obes Metab. 2010 Aug;12(8):641-7. doi: 10.1111/j.1463-1326.2010.01199.x. Review.

PMID:
20590740
17.

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.

Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L.

Cardiovasc Diabetol. 2011 Mar 16;10:22. doi: 10.1186/1475-2840-10-22.

19.

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

Ovalle F.

Clin Ther. 2011 Apr;33(4):393-407. doi: 10.1016/j.clinthera.2011.04.006. Review.

PMID:
21635987
20.
Items per page

Supplemental Content

Write to the Help Desk